In both in vitro and in vivo studies, the inhibition of METTL3 or IGF2BP3 was shown to enhance anti-tumor immunity through the PD-L1-mediated activation, depletion, and infiltration of T cells (149). The gene discussed is CD274; the disease is neoplasm.